DBV Technologies Secures $306.9M to Advance Epicutaneous Immunotherapy for Food Allergies and Beyond

DBV Technologies is thrilled to announce a transformative milestone on our journey to redefine the treatment of food allergies and other immunologic diseases, having successfully raised $306,900,000 in our most recent funding round. As a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively, this significant investment reinforces our commitment to driving innovation in patient care. Our groundbreaking approach, centered on epicutaneous immunotherapy (EPIT) using our proprietary Viaskin™ technology platform, offers a promising new avenue for re-educating the immune system through the skin. The secured funds will be strategically deployed to accelerate clinical trials and expand our research into treatments that address a broad spectrum of unmet medical needs, with an immediate focus on developing the first EPIT treatment for peanut allergy—a condition that continues to impact millions of families globally. In addition to addressing food allergies, this capital infusion will enable DBV Technologies to explore further applications of our innovative technology in treating inflammatory and autoimmune diseases, thereby paving the way for a new class of immunotherapy. This funding not only validates the confidence of our investors in our vision and scientific strategy but also marks a critical step toward delivering safer, more effective treatment options for patients. As we harness these resources to expand our research and clinical efforts, we remain steadfast in our mission to improve patient outcomes and transform lives through advanced therapeutic solutions.